Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TALPHERA, INC. Director's Dealing 2013

May 29, 2013

35181_dirs_2013-05-29_4e841396-d3f9-4774-a605-8df5a5ec39c3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2013-05-24

Reporting Person: ADAMS ADRIAN (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-05-24 Common Stock P 25000 $7.78 Acquired 25000 Direct
2013-05-28 Common Stock P 50000 $8.39 Acquired 75000 Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide AcelRx Pharmaceuticals, Inc. any security holder of AcelRx Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price.

F2: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide AcelRx Pharmaceuticals, Inc. any security holder of AcelRx Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price.